X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organization's scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Recent Posts

ICYMI: New CBO Report highlights biopharmaceutical leadership in the development of new treatments and cures

By Andrew Powaleny  |    April 12, 2021
America’s biopharmaceutical companies are at the heart of a research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. The ongoing...   Read More

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines

By Andrew Powaleny  |    March 8, 2021
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have made unprecedented progress...   Read More

2020 FDA approvals show innovation despite COVID-19 pandemic challenges

By Andrew Powaleny  |    January 26, 2021
A new report from the U.S. Food and Drug Administration (FDA) notes that the Center for Drug Evaluation and Research (CDER) approved 53 novel drugs last year. These figures are in addition to...   Read More

ICYMI: Cancer death rate continues decline due to advances in treatment

By Andrew Powaleny  |    January 19, 2021
For the second year in a row, The American Cancer Society (ACS) reports a record single-year decline in cancer death rates in the United States. Each year, ACS estimates the number of new cancer...   Read More

Report: More than 1,300 medicines and vaccines in development to help fight cancer

By Andrew Powaleny  |    December 15, 2020
Over the last 30 years, significant progress has been made in the fight against cancer. Researchers have expanded their understanding of how cancer develops and how to target medicines for specific...   Read More

Leading researchers to spotlight the critical role of biopharmaceutical R&D

By Andrew Powaleny  |    October 1, 2020
Biopharmaceutical researchers are at the heart of a robust American research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world.   Read More

Summer reading in the age of COVID-19

By Andrew Powaleny  |    August 21, 2020
As the summer of 2020 starts to creep to a close, America’s biopharmaceutical research companies are working around the clock to identify new treatments to reduce COVID-19 infection and vaccines, to...   Read More

The patient perspective navigating COVID-19

By Andrew Powaleny  |    August 11, 2020
As PhRMA members work around the clock to combat COVID-19, the pandemic has had a tremendous impact around the globe. But for those patients who are currently impacted by a health care condition,...   Read More

ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19

By Andrew Powaleny  |    August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...   Read More

New report shows more than 400 medicines and vaccines in development to tackle infectious diseases, including COVID-19

By Andrew Powaleny  |    July 21, 2020
Throughout history, infectious diseases caused by pathogens such as bacteria or viruses have taken a devastating toll on the lives and security of people around the world. With the ongoing COVID-19...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."